The EPS beat is noise from share dilution — ignore it. The real story is the upcoming product revenue catalysts: Flora Sync LF5 launch in June 2026 and DARE to PLAY dispensing in summer 2026. Monitor for: (1) actual revenue figures in Q2/Q3 2026 filings, (2) any capital raise announcement given tight working capital ($540K), and (3) Ovaprene Phase 3 enrollment completion. The stock is a binary catalyst play on product commercialization success, not a fundamental earnings story.
Price Chart
Executive Summary
Daré Bioscience reported Q1 2026 EPS of -$0.20, a 60% beat vs the -$0.50 consensus, but this is a mechanical artifact of a 66% increase in weighted-average shares outstanding (14.5M vs 8.8M a year ago) rather than operational improvement. Revenue was $152K (vs $27K consensus), entirely from Gates Foundation R&D services agreements, not product sales. The company's key catalysts are all future-dated: Flora Sync LF5 commercial launch expected June 2026 (first product revenue), DARE to PLAY dispensing targeted for summer 2026, and Ovaprene Phase 3 enrollment completion expected in 2026 with primary endpoint analysis in 2027. Cash burn was $6.2M in the quarter, leaving $18.5M cash with only $540K working capital — the company will likely need to raise capital before reaching product revenue profitability.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.20 vs consensus -$0.50 (60% beat), but driven by share count increase from 8.8M to 14.5M
- Revenue $152K vs $27K consensus, entirely from Gates Foundation R&D services — no product revenue yet
- Cash and cash equivalents $18.5M at March 31, 2026, down from $24.7M at December 31, 2025 ($6.2M quarterly burn)
- Working capital only $540K — tight liquidity position
- Flora Sync LF5 commercial launch expected June 2026 — first product revenue milestone
- DARE to PLAY dispensing targeted for summer 2026 (Q3) via 503B outsourcing facility Bravado Pharmaceuticals
- Ovaprene Phase 3 trial: second positive DSMB review; enrollment expected to complete in 2026, primary endpoint analysis in 2027
- DARE-HPV advancing to Phase 2 in May 2026 with $10M ARPA-H funding ($9M received)
- Net loss -$3.0M vs -$4.4M a year ago — improvement from lower R&D spend ($0.7M vs $2.3M) due to $3.5M contra-R&D grant funding
- Stock price $2.70 at filing; market cap $41M
Financial Impact
EPS beat of 60% on a -$0.20 actual vs -$0.50 consensus is a mechanical artifact of share dilution, not operational improvement. Revenue of $152K is immaterial for a $41M market cap company. Cash burn of $6.2M/quarter implies ~3 quarters of runway at current spend.
Risk Factors
- Cash runway limited to ~3 quarters at current burn rate — likely needs equity financing before reaching product revenue profitability
- Product revenue from Flora Sync LF5 and DARE to PLAY is unproven and may fall short of expectations
- Ovaprene Phase 3 trial may not meet primary endpoint despite positive DSMB reviews
- Dependence on 503B outsourcing facility Bravado for DARE to PLAY dispensing — state licensing delays could push timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295307 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers